Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06481163
PHASE2

Telacebec (T) Treatment in Adults With Buruli Ulcer (BU). (TREAT BU)

Sponsor: Barwon Health

View on ClinicalTrials.gov

Summary

The goal of this interventional clinical trial is to demonstrate the complete BU lesion healing rate by 52 weeks after treatment initiation, without relapse and/or curative intent excision surgery, after 10-28 days of telacebec (T) treatment. Males and females age 18 and older will be included. • Participants will attend visits every 2 weeks during treatment and thereafter every 2 weeks until week 24 Thereafter they will be followed by visits at weeks 30, 40, and 52. From week 10 to week 52, if the lesion has healed, follow-up visits may be remote.

Official title: A Phase 2 Multicentre, Open-label Study to Evaluate the Efficacy, Safety and Tolerability, and Pharmacokinetics of 14 -28 Days Telacebec Treatment in Adult Participants With Buruli Ulcer.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2024-07-09

Completion Date

2028-01

Last Updated

2026-06-30

Healthy Volunteers

No

Conditions

Interventions

DRUG

Telacebec

The test product will be supplied as Telacebec 100mg tablets.

Locations (2)

Barwon Health

Geelong, Victoria, Australia

Royal Melbourne Hospital

Melbourne, Australia